Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors

Pituitary

Volumn 7, Issue 1, 2004, Pages 21-30

  Freda, Pamela U ^a   Reyes, Carlos M ^a   Nuruzzaman, Abu T ^a   Sundeen, Robert E ^a   Khandji, Alexander G ^a   Post, Kalmon D ^b  

^a Columbia Univ Coll of Phys/Surg ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Cabergoline; IGF I

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLD SENSATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; GONAD FUNCTION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; MALE; MEDICAL ASSESSMENT; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NOSE CONGESTION; OPEN STUDY; PAIN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SIDE EFFECT; SOFT TISSUE DISEASE; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; ERGOLINES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTIN;

EID: 5544284786     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PITU.0000044630.83354.f0     Document Type: Article

References (23)

1. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. Optimizing control of acromegaly: Integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003;88:4759-4767.
2. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013-3018.
3. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant [see comments]. N Engl J Med 2000;342:1171-1177.
4. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21:713-735.
5. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-2343.
6. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group [see comments]. N Engl J Med 1994;331:904-909.
7. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995 49:255-279.
8. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
9. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998 83:3808-3816.
10. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986;63:941-945.
11. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P, Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf) 1988;29:467-476.
12. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537-546.
13. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D. Cabergoline in acromegaly: A renewed role for dopamine agonist treatment? Eur J Endocrinol 1998;139:516-521.
14. Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: A preliminary dose finding study. Clin Endocrinol (Oxf) 1997 46:745-749.
15. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-523.
16. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-3402.
17. Thapar K, Kovacs K, Muller PJ. Clinical-pathological correlations of pituitary tumours. Baillieres Clin Endocrinol Metab 1995;9:243-270.
18. Bassetti M, Arosio M, Spada A, Brina M, Bazzoni N, Faglia G, Giannattasio G. Growth hormone and prolactin secretion in acromegaly: Correlations between hormonal dynamics and immunocytochemical findings. J Clin Endocrinol Metab 1988;67:1195-1204.
19. Melmed S. Acromegaly. N Engl J Med 1990;322:966-977.
20. Lamberts SW, Liuzzi A, Chiodini PG, Verde S, Klijn JG, Birkenhager JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982;12:151-155.
21. Nortier JW, Croughs RJ, Thijssen JH, Schwarz F. Bromocriptine therapy in acromegaly: Effects on plasma GH levels, somatomedin-C levels and clinical activity. Clin Endocrinol (Oxf) 1985;22:209-217.
22. Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: Correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol (Oxf) 2001 54:469-477.
23. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-240.